Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482386 | 1.00 | KDM4A (0.43) | KDM4ATDP1CACNA1HCACNA1BCACNA1C | |
| SCHEMBL29675308 | 0.86 | KDM4A (0.44) | KDM4ATDP1CACNA1HCACNA1BCACNA1C | |
| SCHEMBL22482387 | 0.86 | KDM4A (0.44) | KDM4ATDP1CACNA1HCACNA1BCACNA1C | |
| SCHEMBL24493194 | 0.82 | HDAC10 (0.42) | KDM4AKCNA5GAAHDAC10HDAC6 | |
| SCHEMBL3401610 | 0.81 | CYP17A1 (0.40) | LMNA | |
| SCHEMBL32665148 | 0.81 | KDM4A (0.42) | KDM4ATDP1CACNA1HCACNA1BCACNA1C | |
| SCHEMBL13881841 | 0.80 | AAK1 (0.43) | KDM4ACACNA1HCACNA1BCACNA1CGAA | |
| SCHEMBL2002789 | 0.79 | KDM4A (0.41) | KDM4ATDP1CACNA1HCACNA1BCACNA1C | |
| SCHEMBL25574990 | 0.79 | AAK1 (0.49) | KDM4ACACNA1HCACNA1BCACNA1CKCNA5 | |
| SCHEMBL22469276 | 0.79 | KDM4A (0.39) | KDM4ACACNA1HCACNA1BCACNA1CKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4122537-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3938047-B1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES INC (US) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, NCAPD3 | KDM4A 426/4885TDP1 2051/4885CACNA1H 657/4885 |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | KDM4A 400/4885TDP1 1928/4885CACNA1H 811/4885 |
| US-11548902-B1 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | KDM4A 400/4885TDP1 1928/4885CACNA1H 811/4885 |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | KDM4A 400/4885TDP1 1928/4885CACNA1H 811/4885 |
| US-20230027019-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | KDM4A 400/4885TDP1 1928/4885CACNA1H 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.